At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 153 enrolled
Drug / intervention
Silodosin 8 mg +2 moredrug
Likely dose
Silodosin 8 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Double-Blind, Placebo-Controlled Investigation of Silodosin in the Treatment of Subjects With Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome
In Brief
A Phase 2 clinical trial evaluating Silodosin 8 mg, Placebo, and 1 other intervention for Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Completed, enrolled 153 participants across 22 sites.
Detailed Summary
The primary objective is to compare the efficacy of silodosin 4 and 8 mg once daily with placebo in the treatment of subjects with moderate to severe abacterial chronic prostatitis/chronic pelvic pain syndrome during a 12 week treatment period. The secondary objective is to compare the safety of silodosin 4 and 8 mg once daily with placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2008
Enrollment StartSep 2008
Primary CompletionOct 2009
TodayJul 2026
First PostedAug 25, 2008
Enrollment StartSep 1, 2008
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 17.9 years ago
Interventions
Silodosin 8 mgdrug
Silodosin 8 mg daily
Placebodrug
Placebo
Silodosin 4 mgdrug
Silodosin 4 mg daily